Overview

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Fingolimod Hydrochloride